VISCHER advised Numab in its global alliance with Kaken Pharmaceutical

Numab Therapeutics signed a global development agreement and regional license agreement with Kaken Pharmaceutical for Numab’s novel multi-specific anti-inflammatory drug candidate NM26-2198, which blocks three key pathways in the pathophysiology of atopic dermatitis. The alliance is based on a cooperation and option agreement concluded in 2017. Under the expanded agreement, Kaken will receive commercial rights to NM26-2198 in Japan, China, South Korea, Taiwan, Singapore and Hong Kong, while Numab will retain commercial rights for the US, Europe and the rest of the world. The parties will jointly develop NM26-2198, with Kaken bearing most of the global development costs up to clinical proof of concept.

VISCHER advised Numab on this alliance. The team was led by Stefan Kohler (IP / Life Sciences – pictured) and Christoph Niederer (Tax).

VISCHER advised Numab in its global alliance with Kaken Pharmaceutical


Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2023 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram